FINHUB Insights

EW · Q3 FY25 · Jul 1 – Sep 30, 2025

Edwards Lifesciences Q3 FY25: where the revenue came from and where it went

Edwards Lifesciences Q3 FY25: revenue $1.6B (+15% year over year). Net profit $0.29B. Largest cohort Aortic valve replacement $1.2B. The whole income statement as a sankey diagram from the SEC filing.

Period
Jul 1 – Sep 30, 2025
Reported
Nov 5, 2025 10-Q
Sankey diagram of Edwards Lifesciences's income statement for Q3 FY25: revenue of $1.55 billion splits into segments and flows out into costs, taxes and net profit.

Tap the diagram to enlarge · figures in billions of dollars

Revenue$1.55B +15% year over year
Gross profit$1.21B 78% margin
Operating profit$0.31B 20% margin
Net profit$0.29B 19% margin

The numbers

All figures in billions of U.S. dollars, for Q3 FY25 (period ends Sep 30, 2025).
ItemValueShare of revenueYear over year
Revenue 1.55 100% +15%
Aortic valve replacement 1.15 74% +12%
Surgical heart valve therapy 0.26 17% +8%
Transcatheter mitral 0.15 9% +59%
Cost of revenue−0.3522%
Gross profit1.2178% margin−3pp
R&D−0.2818%−1pp
SG&A−0.5133%+2pp
Other−0.117%+0pp
Operating profit0.3120% margin−6pp
Tax−0.06
Net profit0.2919%−208pp
Filing on EDGAR More quarters of EW

Source of the numbers: structured XBRL data from the filing (10-Q). The diagram is generated automatically and checked against EDGAR before release. How we calculate it → About and methodology.